At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RYZB RayzeBio, Inc.
Halted 12-12 08:08:06 EST
62.49
+0.00
0.00%
High62.49Low62.49Vol0.00
Open62.49D1 Closing62.49Amplitude0.00%
Mkt Cap3.74BTradable Cap2.18BTotal Shares59.92M
T/O17.33MT/O Rate0.00%Tradable Shares34.82M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

No data available

Introduction

Company Name.
RayzeBio, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Issue price:
--